US Spatial Genomics & Transcriptomics Market Size, Share, Trends, Industry Analysis Report - By Technology, Product, End Use (Translational Research, Academic Customers, Diagnostic Customers, Pharmaceutical Manufacturer); Market Forecast, 2025

Description

List of Tables

The US spatial genomics and transcriptomics market size is expected to reach USD 360.96 million by 2034, according to a new study by Polaris Market Research. The report "US Spatial Genomics and Transcriptomics Market Size, Share, Trends, Industry Analysis Report - By Technology, Product, End Use (Translational Research, Academic Customers, Diagnostic Customers, Pharmaceutical Manufacturer); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis of future market growth.

The US spatial genomics and transcriptomics market is experiencing significant growth, driven by advances in precision medicine, increasing research into complex diseases, and the widespread adoption of spatial technologies in both academic and clinical settings. These technologies allow researchers to analyze gene expression and tissue architecture with high spatial resolution, offering critical insights into diseases such as cancer, Alzheimer's, and diabetes. Additionally, the market is supported by substantial investments from government agencies such as the NIH, as well as private sector funding. The demand for spatial genomics in drug development, biomarker discovery, and translational research is fueling market expansion, with both academic institutions and pharmaceutical companies leading the charge.

For instance, in March 2024, a study published in Environmental and Molecular Medicine conducted a review of multi- and single-cell omics for detailed molecular profiling. They also explored the applications of single-cell and multi-omics in cancer, precision medicine, neurobiology, and immunology.

The increasing use of high-throughput sequencing technologies provides a significant opportunity by enabling rapid and thorough analysis of genetic material in various tissue types. This is especially beneficial for studying complex diseases at the molecular level and helps in identifying new therapeutic targets. Additionally, advances in 'inn situ' sequencing and imaging techniques are expanding the capability to directly visualize gene expression within tissues, providing deeper insights into cellular behavior. These innovations, along with growing collaborations between academia, pharmaceutical companies, and healthcare institutions, are fueling the development of new spatial genomics tools, ultimately speeding up progress in personalized medicine and precision therapies.

US Spatial Genomics and Transcriptomics Market Report Highlights

In 2024, the spatial transcriptomics segment dominated the market in the US due to its advanced capabilities in analyzing gene expression with a high spatial resolution that offers a powerful method for creating spatial maps of complex tissues, which is crucial for understanding tissue architecture and disease mechanisms.

The consumables segment accounted for the largest market share in 2024 due to the widespread adoption of consumables and items, including reagents, kits, and sample preparation materials, which are essential for performing a wide range of procedures and analyses.

The translational research segment dominates the US spatial genomics and transcriptomics market due to its critical role in bridging basic science with clinical applications

The global players include 10X Genomics, Akoya Biosciences, Bio-Rad Laboratories, Bio-Techne, BioSpyder Technologies, Cantata Bio, & Danaher Corporation.

Polaris Market Research has segmented the US spatial genomics and transcriptomics market report based on product, technology, application, and end use:

US Spatial Genomics & Transcript Market Segmentation

Product Outlook (Revenue, USD Million, 2020 - 2034)

Instruments
By Mode
Automated
Semi-automated
Manual
By Type
Sequencing Platforms
IHC
Microscopy
Flow Cytometry
Mass Spectrometry
Others
Consumables
Software
Bioinformatics Tools
Imaging Tools
Storage and Management Databases

Technology Outlook (Revenue, USD Million, 2020 - 2034)

Spatial Transcriptomics
Sequencing-Based Methods
Laser Capture Microdissection (LCM)
FFPE Tissue Samples
Others
Transcriptome In-Vivo Analysis (TIVA)
In Situ Sequencing
Microtomy Sequencing
IHC
Microscopy-based RNA Imaging Techniques
Single Molecule RNA Fluorescence In-Situ Hybridization (smFISH)
Padlock Probes/ Rolling Circle Amplification
Branched DNA Probes
Spatial Genomics
FISH
Microscopy-based Live DNA Imaging
Genome Perturbation Tools
Massively-Parallel Sequencing
Biochemical Techniques
Others

End Use Outlook (Revenue, USD Million, 2020 - 2034)

Translational Research
Academic Customers
Diagnostic Customers
Pharmaceutical Manufacturer

Product Code: PM5206

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. US Spatial Genomics & Transcriptomics Market Insights

4.1. US Spatial Genomics & Transcriptomics Market - Market Snapshot
4.2. US Spatial Genomics & Transcriptomics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Growth in Technological Advancements are favoring the U.S. spatial genomics and transcriptomics market
  - 4.2.1.2. Increasing government Funding and Grants in the U.S. spatial genomics and transcriptomics market
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Limited proficiency in spatial genomics and transcriptomics in the U.S. spatial genomics and transcriptomics market
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. US Spatial Genomics & Transcriptomics Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. US Spatial Genomics & Transcriptomics Market, by Product

5.1. Key Findings
5.2. Introduction
- 5.2.1. US Spatial Genomics & Transcriptomics Market, by Technology, 2020-2034 (USD Million)
5.3. Spatial Transcriptomics
- 5.3.1. US Spatial Genomics & Transcriptomics Market, by Spatial Transcriptomics, by Region, 2020-2034 (USD Million)
5.4. By Spatial Genomics
- 5.4.1. US Spatial Genomics & Transcriptomics Market, by By Spatial Genomics, by Region, 2020-2034 (USD Million)

6. US Spatial Genomics & Transcriptomics Market, by Product

6.1. Key Findings
6.2. Introduction
- 6.2.1. US Spatial Genomics & Transcriptomics Market, by Product, 2020-2034 (USD Million)
6.3. Instruments
- 6.3.1. US Spatial Genomics & Transcriptomics Market, by Instruments, by Region, 2020-2034 (USD Million)
6.4. Consumables
- 6.4.1. US Spatial Genomics & Transcriptomics Market, by Consumables, by Region, 2020-2034 (USD Million)
6.5. Software
- 6.5.1. US Spatial Genomics & Transcriptomics Market, by Software, by Region, 2020-2034 (USD Million)

7. US Spatial Genomics & Transcriptomics Market, by End-Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. US Spatial Genomics & Transcriptomics Market, by End-Use, 2020-2034 (USD Million)
7.3. Translational Research
- 7.3.1. US Spatial Genomics & Transcriptomics Market, by Translational Research, by Region, 2020-2034 (USD Million)
7.4. Academic Customers
- 7.4.1. US Spatial Genomics & Transcriptomics Market, by Academic Customers, by Region, 2020-2034 (USD Million)
7.5. Diagnostic Customers
- 7.5.1. US Spatial Genomics & Transcriptomics Market, by Diagnostic Customers, by Region, 2020-2034 (USD Million)
7.6. Pharmaceutical Manufacturer
- 7.6.1. US Spatial Genomics & Transcriptomics Market, by Pharmaceutical Manufacturer, by Region, 2020-2034 (USD Million)

8. US Spatial Genomics & Transcriptomics Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. US Spatial Genomics & Transcriptomics Market Assessment, By Geography, 2020-2034 (USD Million)
8.3. US Spatial Genomics & Transcriptomics Market - North America
- 8.3.1. North America: US Spatial Genomics & Transcriptomics Market, by Technology, 2020-2034 (USD Million)
- 8.3.2. North America: US Spatial Genomics & Transcriptomics Market, by Product, 2020-2034 (USD Million)
- 8.3.3. North America: US Spatial Genomics & Transcriptomics Market, by End-Use, 2020-2034 (USD Million)
- 8.3.4. US Spatial Genomics & Transcriptomics Market - U.S.
  - 8.3.4.1. U.S.: US Spatial Genomics & Transcriptomics Market, by Technology, 2020-2034 (USD Million)
  - 8.3.4.2. U.S.: US Spatial Genomics & Transcriptomics Market, by Product, 2020-2034 (USD Million)
  - 8.3.4.3. U.S.: US Spatial Genomics & Transcriptomics Market, by End-Use, 2020-2034 (USD Million)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. 10X Genomics
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Akoya Biosciences, Inc
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Bio-Rad Laboratories
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. BioSpyder Technologies Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Danaher Corporation
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Genomic Vision SA
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Illumina
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Lunaphore Technologies
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Miltenyi Biotec
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. NanoString Technologies
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. Natera
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
10.12. Optical Biosystems
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development